Market closedADR
Dr. Reddy's Laboratories/$RDY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Hyderabad, India
Employees
27,048
Website
RDY Metrics
BasicAdvanced
$12B
18.34
$0.75
0.37
$0.08
0.59%
Price and volume
Market cap
$12B
Beta
0.37
52-week high
$16.89
52-week low
$12.50
Average daily volume
1.8M
Dividend rate
$0.08
Financial strength
Current ratio
1.918
Quick ratio
1.177
Long term debt to equity
2.357
Total debt to equity
15.886
Dividend payout ratio (TTM)
12.41%
Interest coverage (TTM)
25.15%
Management effectiveness
Return on assets (TTM)
10.32%
Return on equity (TTM)
18.47%
Valuation
Price to earnings (TTM)
18.336
Price to revenue (TTM)
3.156
Price to book
3.14
Price to tangible book (TTM)
4.69
Price to free cash flow (TTM)
141.667
Dividend yield (TTM)
0.59%
Forward dividend yield
0.59%
Growth
Revenue change (TTM)
14.74%
Earnings per share change (TTM)
2.68%
3-year revenue growth (CAGR)
14.51%
3-year earnings per share growth (CAGR)
26.67%
3-year dividend per share growth (CAGR)
16.96%
What the Analysts think about RDY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
RDY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RDY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RDY News
AllArticlesVideos
Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Business Wire·5 days ago
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
Business Wire·1 week ago
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Dr. Reddy's Laboratories stock?
Dr. Reddy's Laboratories (RDY) has a market cap of $12B as of March 23, 2025.
What is the P/E ratio for Dr. Reddy's Laboratories stock?
The price to earnings (P/E) ratio for Dr. Reddy's Laboratories (RDY) stock is 18.34 as of March 23, 2025.
Does Dr. Reddy's Laboratories stock pay dividends?
Yes, the Dr. Reddy's Laboratories (RDY) stock pays dividends to shareholders. As of March 23, 2025, the dividend rate is $0.08083 and the yield is 0.59%. Dr. Reddy's Laboratories has a payout ratio of 12.41% on a trailing twelve-month basis.
When is the next Dr. Reddy's Laboratories dividend payment date?
The next Dr. Reddy's Laboratories (RDY) dividend payment date is unconfirmed.
What is the beta indicator for Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.